Drugs / PEGPLERANIB SODIUM
PEGPLERANIB SODIUM
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02591914 | Feb 2014 → May 2016 | wet macular degeneration | Retinal Consultants of Arizona | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02859441 | Jan 2017 → Jul 2019 | von Hippel-Lindau disease | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT02387957 | Apr 2016 → Jan 2017 | age-related macular degeneration | Ophthotech Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT02214628 | Jul 2014 → Dec 2016 | age-related macular degeneration | Ophthotech Corporation | Terminated | No outcome recorded |
| Phase 2 | NCT01089517 | Mar 2010 → Jun 2012 | age-related macular degeneration | Ophthotech Corporation | Completed | No outcome recorded |
| Phase 33 trials | ||||||
| Phase 3 | NCT01940887 | May 2014 → Jun 2017 | age-related macular degeneration | Ophthotech Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT01944839 | Aug 2013 → Dec 2016 | age-related macular degeneration | Ophthotech Corporation | Terminated | No outcome recorded |
| Phase 3 | NCT01940900 | Aug 2013 → Dec 2016 | age-related macular degeneration | Ophthotech Corporation | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00569140 Comparator | Dec 2007 → Dec 2008 | age-related macular degeneration | Ophthotech Corporation | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PEGPLERANIB SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301576 ↗ |
| Known as | E-01AJ | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301576 ↗ |
| Known as | E10030 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01940887 ↗ |
| Known as | Fovista | “A Phase 3 Safety and Efficacy Study of Fovista® (E10030) Intravitreous Administration in Combination With Lucentis® Compared to Lucentis® Monotherapy” NCT01944839 ↗ |
| Known as | X-01E | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301576 ↗ |
| Action | Inhibit | “Anti-PDGF” NCT00569140 ↗ |
| Modality | Aptamer | “Anti-PDGF Pegylated Aptamer” NCT00569140 ↗ |
| Route | Intravitreal | “Intravitreal injection” NCT00569140 ↗ |
| Target | PDGFB | “Anti PDGF-B Pegylated Aptamer” NCT01944839 ↗ |